Literature DB >> 20105591

Defining hepatoblastoma responsiveness to induction therapy as measured by tumor volume and serum alpha-fetoprotein kinetics.

Harold N Lovvorn1, Dan Ayers, Zhiguo Zhao, Melissa Hilmes, Pinki Prasad, Myrick C Shinall, Barry Berch, Wallace W Neblett, James A O'Neill.   

Abstract

PURPOSE: Hepatoblastoma is commonly unresectable at presentation, necessitating induction chemotherapy before definitive resection. To refine the paradigm for timing of resection, we questioned whether a plateau in hepatoblastoma responsiveness to neoadjuvant therapy could be detected by calculating tumor volume (TV) and serum alpha-fetoprotein (sAFP) kinetics.
METHODS: To calculate TV and sAFP as measures of treatment responsiveness over time, infants having initially unresectable epithelial-type hepatoblastomas were identified at a single institution (1996-2008). Effects of therapy type, therapy duration, and lobe of liver involvement on TV, sAFP, margin status, and toxicity were analyzed.
RESULTS: Of 24 infants treated for epithelial-type hepatoblastoma during this interval, 5 were resected primarily, and 15 had complete digital films for kinetics analysis. Both TV and sAFP decreased dramatically over time (P < .0001). No statistically significant difference in mean TV or sAFP was detected after chemotherapy cycle 2. Left lobe tumors had greater presenting levels of and significantly slower decay in sAFP compared with right lobe tumors (P = .005), although no statistically significant differences in TV existed between liver lobes. Resection margins did not change with therapy duration.
CONCLUSIONS: Measuring TV and sAFP kinetics accurately reflects hepatoblastoma responsiveness to induction therapy. Treatment toxicities may be reduced by earlier resection and tailoring of chemotherapeutic regimens. Copyright 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20105591      PMCID: PMC2852870          DOI: 10.1016/j.jpedsurg.2009.10.023

Source DB:  PubMed          Journal:  J Pediatr Surg        ISSN: 0022-3468            Impact factor:   2.545


  17 in total

1.  Serum alpha-fetoprotein screening for hepatoblastoma in children with Beckwith-Wiedemann syndrome or isolated hemihyperplasia.

Authors:  Carol L Clericuzio; Emily Chen; Dawn Elizabeth McNeil; Timothy O'Connor; Elaine H Zackai; Livija Medne; Gail Tomlinson; Michael DeBaun
Journal:  J Pediatr       Date:  2003-08       Impact factor: 4.406

2.  Randomized comparison of cisplatin/vincristine/fluorouracil and cisplatin/continuous infusion doxorubicin for treatment of pediatric hepatoblastoma: A report from the Children's Cancer Group and the Pediatric Oncology Group.

Authors:  J A Ortega; E C Douglass; J H Feusner; M Reynolds; J J Quinn; M J Finegold; J E Haas; D R King; W Liu-Mares; M G Sensel; M D Krailo
Journal:  J Clin Oncol       Date:  2000-07       Impact factor: 44.544

Review 3.  Childhood cancers: hepatoblastoma.

Authors:  C E Herzog; R J Andrassy; F Eftekhari
Journal:  Oncologist       Date:  2000

4.  Small cell undifferentiated variant of hepatoblastoma: adverse clinical and molecular features similar to rhabdoid tumors.

Authors:  Angela D Trobaugh-Lotrario; Gail E Tomlinson; Milton J Finegold; Lia Gore; James H Feusner
Journal:  Pediatr Blood Cancer       Date:  2009-03       Impact factor: 3.167

5.  Marked response to preoperative high-dose cis-platinum in children with unresectable hepatoblastoma.

Authors:  C T Black; A Cangir; M Choroszy; R J Andrassy
Journal:  J Pediatr Surg       Date:  1991-09       Impact factor: 2.545

6.  Association between surgical margins and long-term outcome in advanced hepatoblastoma.

Authors:  Bryan J Dicken; David L Bigam; Gordon M Lees
Journal:  J Pediatr Surg       Date:  2004-05       Impact factor: 2.545

7.  Combination chemotherapy (vincristine, adriamycin, cyclophosphamide, and 5-fluorouracil) in the treatment of children with malignant hepatoma.

Authors:  A E Evans; V J Land; W A Newton; J G Randolph; H N Sather; M Tefft
Journal:  Cancer       Date:  1982-09-01       Impact factor: 6.860

8.  Treatment of unresectable hepatoblastoma with liver transplantation in the pediatric population.

Authors:  Ernesto P Molmenti; Krissy Wilkinson; Hebe Molmenti; Jay S Roden; Robert H Squires; Carlos G Fasola; Gail Tomlinson; David E Nagata; Lisa D'Amico; M James Lopez; Leo M Savino; Shigeru Marubashi; Edmund Q Sanchez; Robert M Goldstein; Marion F Levy; Walter Andrews; John A Andersen; Goran B Klintmalm
Journal:  Am J Transplant       Date:  2002-07       Impact factor: 8.086

9.  Redefining the role of doxorubicin for the treatment of children with hepatoblastoma.

Authors:  Marcio H Malogolowkin; Howard M Katzenstein; Mark Krailo; Zhengjia Chen; John J Quinn; Marleta Reynolds; Jorge A Ortega
Journal:  J Clin Oncol       Date:  2008-05-10       Impact factor: 44.544

Review 10.  Liver tumors in children.

Authors:  Jason B Litten; Gail E Tomlinson
Journal:  Oncologist       Date:  2008-07-21
View more
  5 in total

1.  Application of 3D Simulation Software in Chemotherapy and Hepatoblastoma Surgery in Children.

Authors:  Jie Liu; Wenli Xiu; Guangqi Duan; Qian Dong
Journal:  Front Surg       Date:  2022-06-01

2.  Can we predict the prognosis of resectable hepatoblastoma from serum alpha-fetoprotein response during preoperative chemotherapy?

Authors:  Hiroaki Fukuzawa; Naoto Urushihara; Koji Fukumoto; Maki Mitsunaga; Kentaro Watanabe; Takeshi Aoba; Shinya Yamoto; Hiromu Miyake; Shiro Hasegawa
Journal:  Pediatr Surg Int       Date:  2012-09       Impact factor: 1.827

3.  Imaging analysis of hepatoblastoma resectability across neoadjuvant chemotherapy.

Authors:  Andrew J Murphy; Gregory D Ayers; Melissa A Hilmes; Kaushik Mukherjee; Kevin J Wilson; Wade M Allen; Israel Fernandez-Pineda; Myrick C Shinall; Zhiguo Zhao; Wayne L Furman; Mary Beth McCarville; Andrew M Davidoff; Harold N Lovvorn
Journal:  J Pediatr Surg       Date:  2013-06       Impact factor: 2.545

4.  Rapid decrease of serum alpha-fetoprotein and tumor volume predicts outcome in children with hepatoblastoma treated with neoadjuvant chemotherapy.

Authors:  Rosa Nguyen; M Beth McCarville; April Sykes; Shenghua Mao; Jianrong Wu; Max R Langham; Wayne L Furman
Journal:  Int J Clin Oncol       Date:  2018-05-09       Impact factor: 3.402

Review 5.  Clinical significance of serum biomarkers in pediatric solid mediastinal and abdominal tumors.

Authors:  John A Sandoval; Linda H Malkas; Robert J Hickey
Journal:  Int J Mol Sci       Date:  2012-01-20       Impact factor: 6.208

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.